These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15756031)

  • 1. Antisense inhibition of methylenetetrahydrofolate reductase reduces cancer cell survival in vitro and tumor growth in vivo.
    Stankova J; Shang J; Rozen R
    Clin Cancer Res; 2005 Mar; 11(5):2047-52. PubMed ID: 15756031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense inhibition of methylenetetrahydrofolate reductase reduces survival of methionine-dependent tumour lines.
    Sekhon J; Pereira P; Sabbaghian N; Schievella AR; Rozen R
    Br J Cancer; 2002 Jul; 87(2):225-30. PubMed ID: 12107847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene.
    Yang DC; Jiang XP; Elliott RL; Head JF
    Anticancer Res; 2001; 21(3B):1777-87. PubMed ID: 11497259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs.
    Verheul HM; Qian DZ; Carducci MA; Pili R
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):329-39. PubMed ID: 17256134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
    Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
    Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS
    Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
    Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
    Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
    Mewani RR; Tang W; Rahman A; Dritschilo A; Ahmad I; Kasid UN; Gokhale PC
    Int J Oncol; 2004 May; 24(5):1181-8. PubMed ID: 15067340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells.
    Vadgama JV; Wu Y; Shen D; Hsia S; Block J
    Anticancer Res; 2000; 20(3A):1391-414. PubMed ID: 10928049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An antisense oligodeoxynucleotide that depletes RI alpha subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells.
    Yokozaki H; Budillon A; Tortora G; Meissner S; Beaucage SL; Miki K; Cho-Chung YS
    Cancer Res; 1993 Feb; 53(4):868-72. PubMed ID: 8428367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors.
    Lee Y; Vassilakos A; Feng N; Jin H; Wang M; Xiong K; Wright J; Young A
    Int J Oncol; 2006 Feb; 28(2):469-78. PubMed ID: 16391803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense-mediated melanoma inhibitor of apoptosis protein downregulation sensitizes G361 melanoma cells to cisplatin.
    Mousavi-Shafaei P; Ziaee AA; Azizi E; Zangemeister-Wittke U
    Anticancer Drugs; 2006 Oct; 17(9):1031-9. PubMed ID: 17001176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides.
    Schaaf A; Sagi S; Langbein S; Trojan L; Alken P; Michel MS
    Urol Oncol; 2004; 22(3):188-92. PubMed ID: 15271313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. siRNA is not more effective than a first generation antisense oligonucleotide when directed against EGFR in the treatment of PC-3 prostate cancer.
    Tsui P; Rubenstein M; Guinan P
    In Vivo; 2005; 19(4):653-6. PubMed ID: 15999529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of STAT3 antisense oligonucleotide on proliferation and apoptosis of non-small cell lung cancer cell line A549].
    Zhu BR; Cai JM; Tang GS; Li BL; Gao F; Cui JG; Liu HC
    Ai Zheng; 2007 Aug; 26(8):820-7. PubMed ID: 17697540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.
    Lee Y; Vassilakos A; Feng N; Lam V; Xie H; Wang M; Jin H; Xiong K; Liu C; Wright J; Young A
    Cancer Res; 2003 Jun; 63(11):2802-11. PubMed ID: 12782585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy.
    Rubenstein M; Tsui P; Guinan P
    Methods Find Exp Clin Pharmacol; 2006 Oct; 28(8):515-8. PubMed ID: 17136230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer.
    Zhang W; Press OA; Haiman CA; Yang DY; Gordon MA; Fazzone W; El-Khoueiry A; Iqbal S; Sherrod AE; Lurje G; Lenz HJ
    J Clin Oncol; 2007 Aug; 25(24):3726-31. PubMed ID: 17704422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
    Hoffman RM
    Methods Mol Med; 2005; 111():297-322. PubMed ID: 15911987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylenetetrahydrofolate reductase (MTHFR): a novel target for cancer therapy.
    Stankova J; Lawrance AK; Rozen R
    Curr Pharm Des; 2008; 14(11):1143-50. PubMed ID: 18473861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.